Please upgrade your browser.
Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases.
Surgery is the most common form of treatment for kidney tumors and often the only treatment necessary to achieve a cure.
TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting
TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago.
What remains in the pipeline of the eighth largest pharmaceuticals company after the recent approval of its last jackpot?
Specifically, the investigation concerns whether the Company misrepresented or failed to disclose that: (1) the FDA had recommended that the Company conduct an additional Phase III trial due to adverse trends in the Company's first Phase III trial; (2) there was a 25% higher rate of death associated with tivozanib therapy compared to the control drug, sorafenib; and (3) almost 90% of patients studied in the single Phase III trial were enrolled from sites in Central and Eastern Europe with inconsistent treatment patterns from those in the United States.
Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX™ in the treatment of metastatic renal cell carcinoma. Two patients with poor prognosis have thus far shown an average survival of about 11 months, which can be compared to the expected median survival of 5 months.
Search results on ASCO.org relating to abstracts presented at the 2013 Annual Meeting that are specific to kidney cancer.
Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced the publication of data demonstrating the ability of its lead product-candidate, Pexa-Vec (JX-594, pexastimogene devacirepvec) to induce functional anti-cancer immunity, both in patients with diverse solid tumor types and in animal models.
Bristol released preliminary data from the early-stage trial on Wednesday, with more detailed results expected to highlight the American Society of Clinical Oncology's annual meeting in Chicago that starts at the end of the month.
An experimental Roche Holding AG drug that helps the immune system attack tumors was well tolerated and demonstrated an impressive effect against a variety of cancers, according to preliminary trial results released on Wednesday.
|Powered by NeonCRM|